Targeting the ubiquitin system in cancer therapy

被引：506
作者：
Hoeller, Daniela [2 ]
Dikic, Ivan [1 ,3 ,4 ]
机构：
[1] Univ Frankfurt, Inst Biochem & Cluster Excellence Macromol Comple, D-60590 Frankfurt, Germany
[2] Innsbruck Med Univ, Div Med Biochem, A-6020 Innsbruck, Austria
[3] Mediterranean Inst Life Sci, Tumor Biol Program, Split 21000, Croatia
[4] Univ Split, Sch Med, Dept Immunol, Split 21000, Croatia
来源：
NATURE | 2009年 / 458卷 / 7237期
关键词：
ACTIVE PROTEASOME INHIBITOR; TUMOR-SUPPRESSOR PROTEIN; KAPPA-B ACTIVATION; P53 NUCLEAR EXPORT; DEUBIQUITINATING ENZYMES; DEPENDENT APOPTOSIS; MULTIPLE-MYELOMA; BINDING DOMAINS; DNA-DAMAGE; LIGASE;
D O I：
10.1038/nature07960
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
The ubiquitin system is a network of proteins dedicated to the ubiquitylation of cellular targets and the subsequent control of numerous cellular functions. The deregulation of components of this elaborate network leads to human pathogenesis, including the development of many types of tumour. Alterations in the ubiquitin system that occur during the initiation and progression of cancer are now being uncovered, and this knowledge is starting to be exploited for both molecular diagnostics and the development of novel strategies to combat cancer.
引用
收藏
页码：438 / 444
页数：7
相关论文
共 75 条
[1]   The development of proteasome inhibitors as anticancer drugs [J].
Adams, J .
CANCER CELL, 2004, 5 (05) :417-421
[2]   DNA damage: ubiquitin marks the spot [J].
Bennett, Eric J. ;
Harper, J. Wade .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2008, 15 (01) :20-22
[3]   The HECT family of E3 ubiquitin ligases: Multiple players in cancer development [J].
Bernassola, Francesca ;
Karin, Michael ;
Ciechanover, Aaron ;
Melino, Gerry .
CANCER CELL, 2008, 14 (01) :10-21
[4]   Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis [J].
Bienko, M ;
Green, CM ;
Crosetto, N ;
Rudolf, F ;
Zapart, G ;
Coull, B ;
Kannouche, P ;
Wider, G ;
Peter, M ;
Lehmann, AR ;
Hofmann, K ;
Dikic, I .
SCIENCE, 2005, 310 (5755) :1821-1824
[5]   MDM2 is a central node in the p53 pathway: 12 years and counting [J].
Bond, GL ;
Hu, WW ;
Levine, AJ .
CURRENT CANCER DRUG TARGETS, 2005, 5 (01) :3-8
[6]  
Brooks CL, 2004, CELL CYCLE, V3, P436
[7]   p53 ubiquitination: Mdm2 and beyond [J].
Brooks, CL ;
Gu, W .
MOLECULAR CELL, 2006, 21 (03) :307-315
[8]   Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes [J].
Cardozo, Timothy ;
Pagano, Michele .
BMC BIOCHEMISTRY, 2007, 8
[9]   C-terminal modifications regulate MDM2 dissociation and nuclear export of p53 [J].
Carter, Stephanie ;
Bischof, Oliver ;
Dejean, Anne ;
Vousden, Karen H. .
NATURE CELL BIOLOGY, 2007, 9 (04) :428-U111
[10]  
Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476
12345678